Pfizer achieved positive results from two Phase III studies of TRUMENBA (Meningococcal Group B Vaccine). Both studies met all primary immunogenicity endpoints, demonstrating immune responses against certain invasive meningococcal B strains. One study included approximately 3,600 healthy individuals 10 through 18 years of age, and the other study included approximately 3,300 healthy individuals 18 through 25.     “We are very pleased with these Phase III data that show immunogenicity and safety...